
Heart Failure with Preserved Ejection Fraction (Diastolic CHF) and SGLT-2 Inhibitor Therapy
2022-01-27
0:00
11:32
The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF).
Now let us dig a bit more into those headlines.
Fler avsnitt från "Hospital and Internal Medicine Podcast"
Missa inte ett avsnitt av “Hospital and Internal Medicine Podcast” och prenumerera på det i GetPodcast-appen.